Prostate Cancer Update Think Tank 1

Select Publications

Akaza H et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: Interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004;34(1):20-8. Abstract

Beer TM et al. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2004;10(4):1306-11. Abstract

Calais Da Silva et al. Phase III intermittent MAB vs continuous MAB. Proc ASCO 2006;Abstract 4513.

Dijkman GA et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997;158(1):160-3. Abstract

Dijkman GA et al. Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group. Eur Urol 1995;27(3):196-201. Abstract

Dreicer R et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63(6):1138-42. Abstract

Eastham JA et al. Cancer and Leukemia Group B (CALGB) 90203: A randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62(Suppl 1):55-62. Abstract

Febbo PG et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11(14):5233-40. Abstract

Freedland SJ et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-9. Abstract

Garzotto M et al. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006;24(3):254-9. Abstract

Goodin S et al. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 2005;23(15):3352-7. Abstract

Hainsworth JD et al. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate-specific antigen levels after primary treatment for prostate cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Clin Genitourin Cancer 2006;4(4):287-92. Abstract

Hussain A et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 2005;23(12):2789-96. Abstract

Janknegt RA. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group. Cancer 1993;72(12 Suppl):3874-7. Abstract

Klotz LH et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58(11):2546-50. Abstract

McKenzie MR et al. Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP). Proc ASCO 2006;Abstract 4631.

Mellado B et al. Phase II trial of weekly docetaxel (D) and complete androgen blockade (CAB) prior to radical prostatectomy (RP) in high-risk localized prostate cancer (PC) patients (pts). Proc ASCO 2006;Abstract 14515.

Opfermann KJ et al. Intermittent hormone therapy in nonmetastatic prostate cancer. Clin Genitourin Cancer 2006;5(2):138-43. Abstract

Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7. Abstract

Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000;355(9214):1491-8. Abstract

Ramsey S et al. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology 2005;66(4):835-9. Abstract

Southwest Oncology Group. Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006;24(18):2828-35. Abstract

Studer UE et al. Immediate versus deferred androgen deprivation in patients with asymptomatic prostate cancer T0-4 N0-2 M0 not suitable for local definitive treatment. Proc American Urologic Association 2005;Abstract 1659.

Taplin ME et al. Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer. Semin Oncol 2001;28(4 Suppl 15):32-9. Abstract